JP2004517810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517810A5 JP2004517810A5 JP2002518956A JP2002518956A JP2004517810A5 JP 2004517810 A5 JP2004517810 A5 JP 2004517810A5 JP 2002518956 A JP2002518956 A JP 2002518956A JP 2002518956 A JP2002518956 A JP 2002518956A JP 2004517810 A5 JP2004517810 A5 JP 2004517810A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- acceptable carrier
- migraine
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 17
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/639,015 US6362234B1 (en) | 2000-08-15 | 2000-08-15 | Water-soluble prodrugs of propofol for treatment of migrane |
| PCT/US2001/025540 WO2002013810A1 (en) | 2000-08-15 | 2001-08-14 | Water-soluble prodrugs of propofol for treatment of migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517810A JP2004517810A (ja) | 2004-06-17 |
| JP2004517810A5 true JP2004517810A5 (https=) | 2008-10-02 |
Family
ID=24562380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002518956A Pending JP2004517810A (ja) | 2000-08-15 | 2001-08-14 | 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6362234B1 (https=) |
| EP (1) | EP1318798A4 (https=) |
| JP (1) | JP2004517810A (https=) |
| CA (1) | CA2419047A1 (https=) |
| WO (1) | WO2002013810A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ES2211151T3 (es) * | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| PL205271B1 (pl) * | 2001-12-28 | 2010-03-31 | Mgi Gp | Kompozycja farmaceutyczna rozpuszczalnego w wodzie proleku propofolu |
| EP1490030B2 (en) * | 2002-03-20 | 2010-07-14 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| CA2480881C (en) * | 2002-04-08 | 2012-09-11 | Guilford Pharmaceuticals, Inc. | Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| DE20215415U1 (de) * | 2002-10-08 | 2004-02-26 | Biotechnologie Gesellschaft Mittelhessen Mbh | Wasserlösliche Medikamentenvorstufen von Propofol |
| CN103405405A (zh) * | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| ZA200504940B (en) * | 2003-01-28 | 2006-09-27 | Xenoport Inc | Amino acid derived prodrugs of propofol, compositions and uses thereof |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
| US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
| US7230003B2 (en) * | 2003-09-09 | 2007-06-12 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
| CN1882548A (zh) * | 2003-10-24 | 2006-12-20 | 奥斯佩克斯制药公司 | 2,6－二异丙基苯酚的pH敏感性前药 |
| WO2005058250A2 (en) * | 2003-12-17 | 2005-06-30 | Mgi Gp, Inc. | Methods of administering water-soluble prodrugs of propofol for extended sedation |
| WO2006017351A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
| CA2571407A1 (en) * | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
| US20080214508A1 (en) * | 2004-09-17 | 2008-09-04 | Mgi Gp, Inc. | Methods of Administering Water-Soluble Prodrugs of Propofol |
| EP1844000B1 (en) * | 2004-12-23 | 2010-01-27 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| NZ565049A (en) | 2005-06-17 | 2012-02-24 | Vital Health Sciences Pty Ltd | A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| WO2007022437A2 (en) * | 2005-08-18 | 2007-02-22 | Auspex Pharmaceuticals, Inc. | Therapeutic agents for the treatment of cancer and metabolic disorders |
| WO2007028104A2 (en) * | 2005-09-02 | 2007-03-08 | Auspex Pharmaceuticals, Inc. | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
| WO2008052044A2 (en) * | 2006-10-26 | 2008-05-02 | Xenoport, Inc. | Use of derivatives of propofol for treating diseases associated with oxidative stress |
| BRPI0811220A2 (pt) | 2007-05-09 | 2014-10-29 | Pharmacofore Inc | Compostos terapêuticos |
| MX2009012125A (es) | 2007-05-09 | 2010-02-18 | Pharmacofore Inc | Compuestos terapeuticos. |
| US20090005444A1 (en) * | 2007-06-21 | 2009-01-01 | Xenoport, Inc. | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus |
| WO2009036322A1 (en) * | 2007-09-14 | 2009-03-19 | Xenoport, Inc. | Use of propofol prodrugs for treating neuropathic pain |
| GB0905834D0 (en) | 2009-04-03 | 2009-05-20 | Seps Pharma Nv | Phosphonyl-containing phenolic derivatives useful as medicaments |
| CN101575349B (zh) * | 2009-06-11 | 2011-07-20 | 中国科学院广州化学研究所 | 一种丙泊酚磷酸酯二钠盐的制备方法 |
| ES2999020T3 (en) | 2010-02-05 | 2025-02-24 | Phosphagenics Ltd | Carrier comprising non-neutralised tocopheryl phosphate |
| JP5399944B2 (ja) * | 2010-02-25 | 2014-01-29 | 信越化学工業株式会社 | リン酸エステル基含有オルガノポリシロキサンの製造方法 |
| JP5502540B2 (ja) * | 2010-03-19 | 2014-05-28 | 信越化学工業株式会社 | リン酸エステル基含有オルガノポリシロキサンの製造方法 |
| EP2552486B1 (en) | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
| CN101885735B (zh) * | 2010-06-23 | 2012-09-12 | 四川大学华西医院 | 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 |
| WO2011161687A1 (en) | 2010-06-23 | 2011-12-29 | Harman Finochem Limited | Process for preparing extra pure 2, 6-diisopropyl phenol |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| CN102260184B (zh) * | 2011-06-09 | 2014-07-02 | 浙江九旭药业有限公司 | 丙泊酚衍生物及其制备方法和应用 |
| CN114712308A (zh) | 2015-12-09 | 2022-07-08 | 磷肌酸有限公司 | 药物制剂 |
| US11331271B2 (en) | 2016-05-27 | 2022-05-17 | The Johns Hopkins University | Buccal, sublingual and intranasal delivery of fospropofol |
| EP3558903B1 (en) | 2016-12-21 | 2024-07-03 | Avecho Biotechnology Limited | Process for phosphorylating a complex alcohol |
| US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
| US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
| US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
| US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
| JP7751569B2 (ja) | 2019-10-22 | 2025-10-08 | ウェストチャイナホスピタル、スーチョワンユニバーシティ | 置換フェノールヒドロキシ酸エステルのｎ含有誘導体、製造及び使用 |
| EP3912621A1 (en) * | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Propofol for diagnosis of primary headache |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| JPH08339002A (ja) * | 1995-04-10 | 1996-12-24 | Ngk Insulators Ltd | 第二高調波発生素子およびその製造方法 |
| US5891875A (en) * | 1996-05-20 | 1999-04-06 | Eli Lilly And Company | Morpholinyl tachykinin receptor antagonists |
| US6254853B1 (en) | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
| US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
-
2000
- 2000-08-15 US US09/639,015 patent/US6362234B1/en not_active Expired - Lifetime
-
2001
- 2001-08-14 WO PCT/US2001/025540 patent/WO2002013810A1/en not_active Ceased
- 2001-08-14 JP JP2002518956A patent/JP2004517810A/ja active Pending
- 2001-08-14 CA CA002419047A patent/CA2419047A1/en not_active Abandoned
- 2001-08-14 EP EP01964036A patent/EP1318798A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517810A5 (https=) | ||
| US12090139B2 (en) | Formulations comprising triptan compounds | |
| US10835512B2 (en) | Methods of treating respiratory syncytial virus infections | |
| US5807571A (en) | Transdermal therapeutic systems for administering indole serotonin agonists | |
| US6569866B2 (en) | Sustained-release nalmefene preparations and method | |
| JP2002519318A5 (https=) | ||
| JP2007507538A5 (https=) | ||
| JP2003528808A5 (https=) | ||
| WO2006058249A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| WO2003080022A3 (en) | Analgesics for nasal administration | |
| CA2302754A1 (en) | Noribogaine in the treatment of pain and drug addiction | |
| JP2004504406A5 (https=) | ||
| Nagai et al. | Bioadhesive dosage forms for nasal administration | |
| JP2013519653A (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| JP2007511544A (ja) | アミロイド症の予防若しくは治療のための組成物および方法 | |
| WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
| JPH08509749A (ja) | 活性物質投与用の経皮治療システム | |
| JP2008511637A5 (https=) | ||
| Mujawar et al. | Nasal drug delivery: problem solution and its application | |
| WO2004006929A1 (ja) | 経鼻吸収用組成物 | |
| JP5134973B2 (ja) | 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ | |
| JP2003509467A5 (https=) | ||
| US20210308048A1 (en) | Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof | |
| JP2000507207A (ja) | 複合注射剤 | |
| Chien | Recent advances in noninvasive systemic delivery of pharmaceuticals and biopharmaceuticals |